The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO GI 2026 | OS of immunotherapy vs SOC in microsatellite stable metastatic colorectal cancer
Guglielmo Vetere, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses findings from a propensity score matched analysis which examined immunotherapy efficacy in microsatellite stable (MSS) metastatic colorectal cancer. Using propensity score matching against standard-of-care treatments (trifluorine/tipiracil, regorafenib, fruquintinib), findings showed immunotherapy strategies (single/double checkpoint inhibitors with/without tyrosine kinase inhibitors) only superior in patients without liver metastases. This interview took place at the 2026 American Society of Clinical Oncology Gastrointestinal Cancers Symposium in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
